Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 9/20 | 0.65 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.59 |
| ▸ | GHSR | Q92847 | 1/20 | 0.58 |
| ▸ | NPY1R | P25929 | 2/20 | 0.57 |
| ▸ | NPY2R | P49146 | 2/20 | 0.57 |
| ▸ | NPY4R | P50391 | 2/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30380084 | 1.00 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL31514538 | 1.00 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL29361083 | 1.00 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL30276213 | 0.97 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL30276250 | 0.97 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL11410468 | 0.97 | IL23R (0.64) | IL23RUTS2RGHSRKISS1R | |
| SCHEMBL11410421 | 0.97 | IL23R (0.64) | IL23RUTS2RGHSRKISS1R | |
| SCHEMBL31091578 | 0.97 | IL23R (0.66) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL29938267 | 0.96 | IL23R (0.61) | IL23RUTS2RGHSRKISS1R | |
| SCHEMBL29938179 | 0.96 | IL23R (0.61) | IL23RUTS2RGHSRKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201644-A | Ligand compounds comprising chelating groups as bridging groups | 慕尼黑工业大学 | 2024-06-14 | — | — | CN | claimed |
| EP-4380629-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2024-06-12 | — | — | EP | claimed |
| WO-2023012282-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2023-02-09 | — | — | WO | claimed |
| CN-119630622-A | Silicon-based fluoride acceptor groups for radiopharmaceuticals | 慕尼黑工业大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-119013051-A | Composition treatment of small cell lung cancer | 同位素技术慕尼黑有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118201644-A | Ligand compounds comprising chelating groups as bridging groups | 慕尼黑工业大学 | 2024-06-14 | — | — | CN | disclosed |
| EP-4380629-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2024-06-12 | — | — | EP | disclosed |
| EP-4337270-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2024-03-20 | — | — | EP | disclosed |
| CN-117320759-A | Radiopharmaceutical somatostatin receptor ligands and precursors thereof | 慕尼黑工业大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-116981487-A | Combination of para-aminohippuric acid (PAH) and radiolabeled complexes for the treatment of cancer | 同位素技术慕尼黑有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116806144-A | Stable formulations of radionuclide complexes | ITM索卢钦股份有限公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2023012282-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022238553-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-11-17 | — | — | WO | disclosed |
| CN-115212322-A | Freeze-dried medicine box for preparing radioactive medicine and preparation method thereof | 原子高科股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-114126654-A | Para-aminohippuric acid (PAH) as a kidney protective substance | 同位素技术慕尼黑有限公司 | 2022-03-01 | — | — | CN | disclosed |